The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market-centered on minimally invasive diagnosis and treatment of pancreatic and biliary disorders-was valued at approximately USD 2.17 billion in 2024. Expected to surge to USD 3.51 billion by 2030, it’s tracking at a compelling CAGR of 8.26% from 2025 to 2030.

Why Momentum Is Gaining

Rising Disease Burden: An increase in gallstones, pancreatitis, bile duct obstructions, and related gastrointestinal conditions is fuelling demand for ERCP procedures-thanks to their effectiveness and faster recovery compared to open surgery.

Tech Evolution: Breakthroughs like high-definition imaging, enhanced maneuverability and therapeutic accessories are elevating ERCP’s precision and safety. In August 2024, Ambu secured CE approval for its next-generation duodenoscope solutions, further catalyzing adoption.

Shift to Outpatient Care: ERCP procedures are increasingly performed in outpatient settings-such as ambulatory surgery centers and diagnostic clinics-thanks to improved efficiency, convenience, and cost benefits.

Market Breakdown: What’s Dominating?

By Product:

Endotherapy Devices (e.g. stents, sphincterotomes, guidewires) led the pack with 37.1% market share in 2024, driven by their procedural utility and lower overall cost compared to surgical alternatives.

Endoscopes are on the fastest growth track-driven by demand for disposable, high-def, flexible designs that improve imaging and access.

By End-Use:

Outpatient Facilities held the largest share at 53.6% in 2024, expected to continue leading as minimally invasive outpatient procedures gain traction.

Hospitals also show robust growth, supported by rising facility numbers and equipment utilization worldwide.

By Procedure:

Biliary sphincterotomy currently leads, credited for symptom relief and complication management.

Pancreatic sphincterotomy is set for fastest growth, as indications to improve digestive flow and prevent pancreatitis rise.

Regions: Who’s Leading and Who’s Accelerating

North America dominated with 50.1% share in 2024, powered by high procedure rates, advanced infrastructure, and disposable scope demand.

Asia-Pacific is emerging fastest-thanks to expanding healthcare infrastructure, favorable regulations, and inflow of foreign investments.

Europe, Latin America, and MEA are also on growth trajectories, buoyed by aging populations, rising cancer rates, and expanding awareness of minimally invasive treatments.

For More Details or Sample Copy please visit link @: Endoscopic Retrograde Cholangiopancreatography Market Report

Big Players & Strategic Moves

Key leaders shaping the ERCP space include:

Olympus, CONMED, Boston Scientific, Medtronic, Ambu, Fujifilm, Cook, HOYA, Karl Storz, Telemed, and others.

Notable developments:

March 2024: Olympus and NTT launched a cloud-based endoscopy imaging system-ushering in connected diagnostics.

November 2023: HOYA consolidated its reprocessing edge by acquiring Wassenburg Medical.

January 2024: Canon and Olympus joined forces to co-develop advanced endoscopic ultrasound (EUS) systems

Final Take: Why This Market Demands Attention

If you’re in medtech, healthcare provision, or diagnostics-this isn’t just growth. It’s transformation. Here's why you should care:

Disposables and Devices Are Where the Growth Is: Innovators in endotherapy tools and next-gen scopes will lead the charge.

Outpatient Is the New Frontline: Efficiency and convenience make outpatient ERCP the winning channel.